Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

24.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Rab Proteins01:14

Rab Proteins

5.4K
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous lipid emulsion improves recovery time and quality from isoflurane anaesthesia: a double-blind clinical trial.

Basic & clinical pharmacology & toxicology·2014
Same author

Improvement of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for identification of clinically important Candida species.

Clinical laboratory·2014
Same author

Genetic engineering of the green alga Chlorella zofingiensis: a modified norflurazon-resistant phytoene desaturase gene as a dominant selectable marker.

Applied microbiology and biotechnology·2014
Same author

Successful one-stage extraction of an intracardiac and intravenous leiomyoma through the right atrium under transesophageal ultrasound monitoring.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2014
Same author

A particle swarm optimization variant with an inner variable learning strategy.

TheScientificWorldJournal·2014
Same author

Integrative Analysis of Cancer Diagnosis Studies with Composite Penalization.

Scandinavian journal of statistics, theory and applications·2014

Related Experiment Video

Updated: Mar 16, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.9K

MiR-329 suppresses osteosarcoma development by downregulating Rab10.

Wenwei Jiang1, Jin Liu2, Tianyang Xu1

  • 1Department of Orthopedics, Shanghai Tenth People's Hospital, Tong Ji University School of Medicine, China.

FEBS Letters
|August 4, 2016
PubMed
Summary
This summary is machine-generated.

MicroRNA-329 (miR-329) acts as a tumor suppressor in osteosarcoma, with its downregulation linked to advanced stages. Restoring miR-329 inhibits cancer cell growth, promotes apoptosis, and reduces tumor formation.

Keywords:
Rab10growthmiR-329migrationosteosarcoma

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 16, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.9K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The function of microRNA-329 (miR-329) as a tumor suppressor is established in several cancers, but its specific role in osteosarcoma pathogenesis is not well understood.
  • Osteosarcoma is a primary bone malignancy with significant mortality, necessitating further research into its underlying molecular mechanisms.

Discussion:

  • This study investigates the expression and function of miR-329 in osteosarcoma, revealing its potential as a therapeutic target.
  • The findings highlight the critical role of miR-329 in regulating key cellular processes relevant to osteosarcoma progression, including proliferation, apoptosis, and cell cycle control.
  • The identification of Rab10 as a direct target of miR-329 provides a molecular mechanism through which miR-329 exerts its tumor-suppressive effects.

Key Insights:

  • MiR-329 is significantly downregulated in osteosarcoma tissues and correlates with advanced disease stages.
  • Overexpression of miR-329 inhibits osteosarcoma cell proliferation, induces apoptosis, and causes G0/G1 cell cycle arrest.
  • MiR-329 suppresses osteosarcoma cell migration, invasion, and in vivo tumorigenicity, with Rab10 identified as a key mediator.

Outlook:

  • MiR-329 represents a potential biomarker for osteosarcoma prognosis and a therapeutic agent for treating this bone cancer.
  • Further research into the miR-329/Rab10 axis could uncover novel therapeutic strategies for osteosarcoma.
  • Understanding the regulatory network of miR-329 in osteosarcoma will advance the field of bone cancer research.